Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Kinarus’ KIN001 shows strong antiviral activity against BA.2 and BA.5 Omicron subvariants

The phase 2 trial of KIN001 in ambulatory COVID-19 patients is actively recruiting

A designer evaluating user research findings on a laptop

Demonstrating the value of UX research in pharma and healthcare

Demonstrating the value of UX research in pharma and healthcare can be difficult. Here, Graphite's Senior Clinical UX Researcher, Jack Burton, explains the importance of user research within the digital...

Graphite Digital

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings

After more than two years of pandemic restrictions, many Pharma leaders are itching to meet with their key opinion leaders (KOLs) face-to-face again, believing that’s what most KOLs want. It may...

Impetus Digital

- PMLiVE

imc Group announces its rebrand as SCIRIS

SCIRIS offer tailored healthcare communications, medical compliance and brand strategy

- PMLiVE

INTRODUCING SCIRIS

imc group reveals new brand identity

Porterhouse Medical Group

- PMLiVE

NHS England set to be first in world to eliminate hepatitis C by 2030

Deaths from the virus fell by 35% following an antiviral drugs deal worth almost £1bn

- PMLiVE

WHO and EC expand strategic plans to deliver better health security

The partnership will reinforce areas highlighted in the EU Global Health Strategy

- PMLiVE

Novartis announces positive phase 3 results for prostate cancer drug Pluvicto

The study met its primary endpoint of radiographic progression-free survival

- PMLiVE

FDA approves Rigel’s Rezlidhia for acute myeloid leukaemia

Phase 2 data showed a complete remission rate of 35% and median duration of 25.9 months

- PMLiVE

Pfizer and Roivant form new company to develop inflammatory disease drug

RVT-3101 is currently being evaluated in a global phase 2b study for ulcerative colitis

- PMLiVE

Influenza – the risk to vulnerable populations

Why we can't get complacent about flu vaccination

- PMLiVE

World-first trial launches in UK to assess stem cell transplants as first-line MS treatment

The £2.3m StarMS study will compare AHSCT with four other drug treatments

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links